MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials On the back of highly promising Phase Ib data, MinervaX has...
MinervaX announces award of 4.4 million euro in investment from Novo Holding's repair impact fund and Sunstone Life Science Ventures for further clinical development of the company's vaccine against...
MinervaX initiates phase I clinical trial with innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns. Novel, single component vaccine predicted to protect...
Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. MinervaX, a privately held Danish biotech company,...
Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. NeoStrep, a consortium consisting of Lund University...
MinervaX announces the award of a Eurostars Grant in collaboration with Bioneer (Denmark), The Danish Technical University (Denmark) and Telormedix (Switzerland) for the development of a LIPODEL...
MinervaX Announces the award of a grant from The Danish National Advanced Technology Foundation together with The State Serum Institute and University of Copenhagen for the development and testing...
MinervaX Announces the award of a 500,000 DKK (66,000 EUR) grant from the Ministry of Science, Technology and Innovation — “Videnkupon”. MinervaX, a private biotech company developing a novel...
